A potential new antidepressant and antianxiety treatment with a unique mechanism of action has been developed by scientists at the University of Bath.
The compound has shown significant potential after studies in mice. The research is published in the British Journal of Pharmacology.
Around one in six adults will experience depression in their lifetimes. New drugs to treat depression in particular are needed because many existing antidepressants don’t work in up to 50% of patients. This new University of Bath compound, known as BU10119, works in a different way to the most common antidepressant drugs; selective serotonin reuptake inhibitors (SSRIs), and may therefore offer a new potential treatment for those in whom SSRIs don’t work.
Unlike SSRIs which target the serotonin system in the brain, BU10119 works by blocking receptors called kappa opioid receptors. Blocking these receptors has been shown to have anti-depressant like effects in mice.
In a series of laboratory trials, mice given BU10119 demonstrated behaviours consistent with providing antidepressant–like effects.
Dr Sarah Bailey, Senior Lecturer in the Department of Pharmacy & Pharmacology at the University of Bath, said: “I’m really quite excited by the potential of this compound. Developing new medicines is why I got into pharmacology and, in 20 years of research, this is the closest I have come to a new compound that might translate towards the clinic. It’s promising, but that said, we are still at an early stage, these experiments are in mice and further research is still required for example to establish safety.
“SSRIs can work very well for some patients, but we know they don’t work for everyone which is one reason why developing new antidepressant and antianxiety drugs could be really beneficial.”
The researchers were inspired to develop the compound after previous University of Bath research showed that a combination of two existing drugs, buprenorphine and naltrexone, had potential as an antidepressant. BU10119 combines the effects of this combination in one drug.
Professor Stephen Husbands, Head of Medicinal Chemistry at the University of Bath added: “This research builds on our previous work which showed that combining buprenorphine and naltrexone can give antidepressant effects in mice. By combining the effects of both drugs in one molecule we hope that a safe and effective drug will eventually be the outcome. BU10119 is part of a series of compounds now licensed to, and under development with, Orexigen Therapeutics.”
The study was funded a by a National Institute on Drug Abuse grant and a PhD scholarship from the Government of Saudi Arabia.
The University of Bath has signed the Concordat on Openness on Animal Research. The University is committed to enhancing our communications with the media and public about our research using animals. Find out more: http://www.bath.ac.uk/collections/animal-research/
The Latest on: Depression and anxiety
- How Clutter Can Trigger Anxiety, Stress & Depressionon February 2, 2020 at 12:56 pm
If you've ever noticed how calm you feel in a clean room, it's not just in your head. There's science to back up the claim that messy, cluttered spaces lead to a messy, cluttered mind -- in the form ...
- Troubled relationships may double depression and anxiety riskson February 2, 2020 at 3:15 am
In a new study, researchers found that some forms of domestic violence double victims’ risk of depression and anxiety disorders later in life. The research was conducted by a team at the ...
- Manny’s: When Depression And Anxiety Have A Voice- Book Signingon February 1, 2020 at 12:11 am
« Atlas Cafe: Ragtime Red Poppy Art House: February 1st MAPP: Make Love Not War / Haz el Amor y no la guerra » ...
- Psychedelic compound found in magic mushrooms may help with anxiety and depression in cancer patientson January 31, 2020 at 11:00 pm
In a landmark study carried out in 2016, the team found that psilocybin combined with psychotherapy sessions produced immediate, substantial, and sustained improvements in anxiety and depression and ...
- 7 Best Mental Health Apps for Depression and Anxietyon January 31, 2020 at 6:59 am
These applications have developed to give the right solutions to the people suffering from acute depression, anxiety or have suicidal tendencies. Is Mental Health Apps the end of Therapy? Of course ...
- An advertising watchdog alleges Goop violated a court order by claiming candles and perfumes can ‘ease OCD, anxiety, and depression’on January 30, 2020 at 8:30 am
Gwyneth Paltrow's company was ordered to stop saying its products could treat medical ailments. An organization is now saying it hasn't.
- 5 years after taking one dose of 'magic' mushrooms, a group of cancer patients still feel less depression and anxietyon January 29, 2020 at 8:10 am
A trial at NYU led 15 cancer survivors through a therapy session on psychedelics. Five years on, they reported feeling less anxiety and depression.
- Psilocybin in magic mushrooms may help reduce depression and anxiety among cancer patients, finds studyon January 29, 2020 at 1:52 am
A single dose of psilocybin, a compound found in "magic mushroom", might be able to lower symptoms of long-term depression and anxiety among cancer patients, a new study finds. The study participants ...
- Anxiety Disorders and Depression Treatments Market Growth 2020 - Porters of Analysis, Research Report Till 2026on January 28, 2020 at 9:07 pm
Anxiety and depression are the most common forms of psychiatric disorders, which are known to have affected a majority of the global population. Depression is a mental disorder, while anxiety refers ...
- Psychedelic Mushrooms Can Help Ease Anxiety and Depression in Cancer Patients for Years, Scientists Believeon January 28, 2020 at 7:29 am
Taking a single dose of a psychedelic compound found in magic mushrooms can ease symptoms of anxiety and depression in cancer patients for years, according to a study. Almost five years after taking ...
via Google News and Bing News